Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

From advances in targeted therapies to the integration of AI and steps towards precision medicine, 2024 brought many exciting developments in the field. With 2025 now unfolding, many of these are likely to continue gaining momentum and potentially redefine patient care. In this latest edition of touchREVIEWS in RMD, we’re excited to present a collection […]

Diamant Thaçi, EADV 2020: Long-term Efficacy of Tildrakizumab in Psoriasis

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 16th 2020

It was an honour to talk with Prof. Diamant Thaçi (University of Lübeck, Lübeck, Germany) about the reSURFACE clinical studies and in particular, long-term data from reSURFACE 2 (NCT01729754).  Results from the study, which investigated the anti-IL-23p19 monoclonal antibody, tildrakizumab in the treatment of patients with moderate-to-severe plaque psoriasis, were presented in the abstract entitled ‘Long-term efficacy of tildrakizumab in European patients with moderate-to-severe plaque psoriasis from the 5-year reSURFACE 2 phase 3 trial‘ (P1754) at the EADV Virtual Congress, 29-31 October 2021.

Questions

  1. What is the rationale for the use of tildrakizumab in the treatment of patients with moderate-to-severe plaque psoriasis? (0:08)
  2. Could you tell us a little about the reSURFACE 1 and reSURFACE 2 clinical studies and their findings? (0:26)
  3. What has the latest data taught us about the long-term efficacy and safety of tildrakizumab in this treatment setting? (1:05)
  4. How can we identify patients most likely to respond to tildrakizumab? (1:45)
  5. How does the efficacy and safety of tildrakizumab compare with other agents that also target IL-12, or specifically IL-17? (2:47)

Disclosures: Diamant Thaçi is a lecturer and/or consultant for AbbVie, Almirall, Amgen, Asana Biosciences, Biogen Idec, BIOCAD, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, DS-Biopharma, GlaxoSmithKline, Janssen-Cilag, Kyowa Kirin, Leo Pharma, Eli Lilly, Novartis, Regeneron, Sandoz, Sanofi-Aventis and UCB, and received grants from AbbVie and Novartis (paid to institution).

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.

Filmed in coverage of the ACR Convergence 2020 (Virtual).

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup